Regeneron to buy bankrupt 23andMe, vows ethical use of customer DNA data

Regeneron Pharmaceuticals will acquire bankrupt genomics firm 23andMe for $256 million, gaining access to over 15 million customer DNA profiles to bolster its genomics-driven drug discovery efforts. The deal follows 23andMe's bankruptcy filing after a data breach and declining consumer demand, raising data privacy concerns among U.S. lawmakers; Regeneron has pledged to uphold existing privacy policies and work with an independent overseer to ensure ethical use of customer data, though Bernstein analysts suggest it may take a decade or more to see a return on the investment.

Analysis

Regeneron Pharmaceuticals (REGN.O) is set to acquire the bankrupt genomics firm 23andMe Holding for $256 million via a bankruptcy auction, a strategic move aimed at significantly enhancing its drug discovery capabilities by integrating 23andMe's extensive database of over 15 million customer DNA profiles. This acquisition follows 23andMe's financial distress, precipitated by declining consumer demand for its core ancestry testing services and a significant 2023 data breach that compromised millions of customer records. The transaction, expected to close in Q3, brings data privacy to the forefront, a concern amplified by the prior breach and scrutiny from U.S. lawmakers. Regeneron has committed to upholding 23andMe's existing privacy policies, complying with data protection laws, and cooperating with a court-appointed independent overseer tasked with assessing the deal's privacy implications; this overseer's report is due by June 10, with court approval for the transaction scheduled for June 17. While the acquisition is viewed as strategically sound for Regeneron's long-term genomics research, analysts, such as Bernstein's William Pickering, caution that tangible returns on this investment might take a decade or more to materialize. The deal excludes 23andMe's telehealth service, Lemonaid Health, which will be shuttered, and 23andMe will operate as a wholly owned unit of Regeneron post-acquisition. The overall market sentiment is neutral, with a slightly positive sentiment specific to Regeneron, reflecting a cautious optimism about the long-term potential despite the inherent risks and extended timeline for returns.

Key Decisions for Investors

• Investors should view Regeneron's acquisition of 23andMe as a long-term strategic investment in genomic data, recognizing that financial returns may not be evident for over a decade.
• Monitor the upcoming court approval on June 17 and the findings of the independent privacy overseer's report due June 10, as these will be critical in assessing regulatory and reputational risks associated with customer data handling.
• Consider the potential for enhanced drug discovery capabilities for Regeneron, but weigh this against the challenges of integrating 23andMe and mitigating concerns stemming from its past data breach and financial instability.
• Factor in the low immediate market impact score (0.3) and neutral overall sentiment, suggesting the market is adopting a wait-and-see approach, which may present opportunities for long-term investors comfortable with the specified risk profile and timeline.